Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ocugen, Inc.

Equities

OCGN

US67577C1053

Real-time Estimate Cboe BZX
Other stock markets
 18:57:29 29/04/2024 BST 		5-day change 1st Jan Change
1.405 USD +9.77% Intraday chart for Ocugen, Inc. +15.33% +148.71%
04-22 Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating MT
04-22 Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
GL
Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
PR
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
NE
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
GL
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
PR
Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating
MT
Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating
MT
Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
PR
OCGN Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
MT
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
GL
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy
CI
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
PR
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
PR
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
NE
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
OCUGEN TO PARTICIPATE IN FIRESIDE CHAT AT THE EMERGING GROWTH VIRTUAL HEALTHCARE EQUITY CONFERENCE, PRESENTED BY NOBLE CAPITAL MARKETS
AQ
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.